NCT07612280
Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Essential Thrombocythemia (ET) and Polycythemia Vera (PV) With Thrombocytosis
At risk: Primary completion moved at least 2 years 7 months later, primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Jan 30, 2031 Show 7 more changesShow less
- Primary endpoint(s) modified
- Enrollment increased: 30 → 70 participants
- Eligibility criteria shortened, about 1,393 words
- Secondary endpoints: 8 to 3
- Study description shortened, about 1,461 words
- Site details revised at 2 of 7 sites
- Study title shortened, about 3 words
- Minor Trial sites expanded: 1 → 7 locationsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Dose Escalation - Incidence of Dose-Limiting Toxicities (DLTs)
Timeframe: At the end of Cycle 1 (each cycle is 28 days)
Dose Expansion - Platelet count
Timeframe: Up to 2 years
Secondary (3)
Dose Escalation - Incidence of Treatment-Emergent Adverse Events (TEAEs)
Pharmacokinetic measures
Measures of clinical activity
Arms and interventions
Dose Escalation: Escalating oral dose of JBI-802Experimental
JBI-802 - CoREST inhibitor (Dual LSD1 and HDAC6 inhibitor)
Dose Expansion: Expansion arm at the RP2D of oral JBI-802Experimental
Drugs: JBI-802
Sites
7 sites in 1 country